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Phenotype and genetic studies in the patient with MYST4 haploinsufficiency at age 6 years. (A) Note the mild funnel chest and the genua valga 
and facial dysmorphism (B–D) with blepharophimosis, ptosis, high arched eyebrows, low-set ears, smooth philtrum, and retrognathia and a high 
arched palate. Ptosis was surgically treated at age 5 and 6 years. (E) Representative metaphase spread of the patient using the BAC clone RP11-
668A2 (red, arrows), with hybridization signals localized on both derivative chromosomes, spanning the breakpoint region. Original magnifica-
tion, ×1,000. (F) Breakpoint sequencing after long-range PCR indicating the breakpoint (red dotted line) disrupting the MYST4 gene in intron 3. 
Chr., chromosome. (G) Relative mRNA expression levels of the haploinsufficient MYST4 gene and the TUBGCP3 gene 3′ of the breakpoint 
region in the peripheral blood of the patient (P) and 3 healthy age-matched controls (C1–C3). Note the significant decrease of MYST4 expression 
levels in the patient (*P < 0.001, t test) but unchanged relative expression levels of TUBGCP3 (**P < 0.8, t test). RQ, relative quantification.
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Structure and histone acetylation of MYST4. (A) Three MYST4 isoforms have been identified (MORF, MORFα, and MORFβ) to differ in the 
negative regulator for HAT domain (NRHD) coded by exon 8. The red line indicates the site of translocation (exon 3/4 boundary at amino acid 
position 207) with respect to protein structure. Note histones H1- and H5-like domain (H15), C4HC3 PHD-zinc fingers (PHD), and the N-terminal 
part of Enok, MOZ, or MORF (NEMM). Numbers represent amino acids. NH2, N-terminal end of the protein; 2x PHD, 2-times PHD domain; 
C2HC, zinc finger motif domain. (B) Time course of histone acetylation activity in a cell line of the patient compared with that of controls (Ctrls). 
(C) Significant decrease of global H3 (*P < 0.05, t test) but normal H4 acetylation in the patient (t test).
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Effect of different MYST4 siRNAs on H3 and H4 acetylation. (A) 
Results of quantitative RT-PCR revealed significantly reduced 
MYST4 mRNA expression levels in both cell lines (*P < 0.05, t test), 
HEK293 and HeLa, after exposure to 3 different MYST4 siRNAs 
(1, HSS118879; 2, HSS118880; 3, HSS118881). (B) Significant 
decrease of global H3 but (C) normal H4 acetylation was confirmed 
in HEK293 and HeLa cell lines (*P < 0.05, t test; **P < 0.00001, 
t test). Note the correlation between MYST4 depletion levels and loss 
of H3 acetylation (P < 0.02793, rank correlation coefficient) but not H4 
acetylation (P < 0.9349, rank correlation coefficient). Based on these 
results the siRNA HSS118880 was used for further analysis. Numbers 
in the bars are the relative quantification.
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Qkfgt/gt mutant mice deficient in Myst4. Qkfgt/gt mutant 
mice deficient in MYST4 exhibit facial and skeletal 
abnormalities. (A–C) External appearance of Qkfgt/gt 
mutant mice versus that of controls at 7 weeks of age. 
(D and E) Close-up images of the eyes. (F and G) 
Skeletal preparation of the lower jaw. (H–K) β-Galac-
tosidase reporter activity (blue) representing the high 
Qkf gene expression domains (H and I) in cartilage 
primordia of the developing skeletal system at E15.5, 
(J) primordia of the cerebral cortex and skeletal ele-
ments at E12.5, and (K) the adult parietal cortex (Ctx) 
and hippocampus (Hi). (L) Endogenous Qkf mRNA 
detected by in situ hybridization in skeletal primordia 
of the E15.5 hind limb (precipitated silver grains cor-
responding to Qkf mRNA appear white in dark-field 
image). Arrows indicate coronoid process in F and G, 
strongly Qkf–β-galactosidase–positive cells in H and I, 
telencephalon and mandibular process in J and K, and 
endogenous Qkf mRNA expressing cells in skeletal 
primordia in L. (M) In mice, the tibia and the fibula nor-
mally fuse in their distal third. (M) The Qkfgt/gt mutant 
mice lack the fusion of the tibia and fibula (N) nor-
mally observed in wild-type mice. Scale bar: 190 μm 
(H); 65 μm (I); 160 μm (J); 790 μm (K); 910 μm (L); 
and 3.6 mm (M and N).
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Myst4 deficiency alters growth plate in mice. (A, C, E, and G) Wild-
type and (B, D, F, and H) Qkfgt/gt mutant growth plates. (A, B, E, and 
F) Toluidine blue/fast green, (C and D) safranin O/fast green, and (G 
and H) Masson’s trichrome–stained sections of (A and B) E15.5 distal 
femur, (C and D) E18.5 proximal and (E–H) distal femur. (A and B) 
Disorganization in the Qkfgt/gt mutant hypertrophic (H) region was 
visible at E15.5 and (C–F) more pronounced at E18.5 and enlarged in 
G and H. Arrows delineate the border of the hypertrophic zone. Note 
the poor demarcation between the Qkfgt/gt proliferative (P), hypertro-
phic, and chondrolytic (C) regions, as compared with those of wild-
type regions, particularly in F versus E (indicated with white lines), the 
reduced height of the hypertrophic region (167 μm in E versus mean 
height of 136 μm in F; P value < 0.05), and the aberrant columnar 
structure in the hypertrophic region (H versus G). Scale bar: 55 μm (A 
and B); 180 μm (C and D); 95 μm (E and F); and 90 μm (G and H).
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MYST4 insufficiency causes enhanced phosphorylation of major genes 


















reveal  that  the H3 histone acetylase MYST4 primarily  regu-
Table 1
Significant KEGG pathways — HEK293/HeLa MYST4 siRNA expression versus control expression
	 Pathway-Express	calculation	 DAVID	functional	annotation
	 P	value	 	 	
KEGG	pathway	name	 Rank	 No.	genes	 %	Pathway	genes	 Uncorr.	 Corr.	γ	 Rank	 Fold	 P	value
	 	 in	pathway	 in	input	 	 	 	 enrichment
Insulin signaling pathway 3 138 6.5 9.71 × 10–9 3.20 × 10–8 1 3.22 5.98 × 10–3
MAPK signaling pathway 4 265 4.2 2.49 × 10–8 4.94 × 10–8 2 2.03 3.92 × 10–2
Wnt signaling pathway 5 148 6.1 1.81 × 10–8 7.56 × 10–8 3 2.85 1.20 × 10–2
Melanoma 6 71 9.9 2.90 × 10–8 8.82 × 10–8 4 4.86 2.75 × 10–3
Apoptosis 7 84 8.3 9.43 × 10–8 2.93 × 10–7 5 3.99 7.30 × 10–3
Regulation of actin cytoskeleton 8 211 4.3 3.47 × 10–7 6.94 × 10–7 6 2.24 3.11 × 10–2
GnRH signaling pathway 9 97 7.2 2.55 × 10–7 9.11 × 10–7 7 3.57 1.24 × 10–2
Glioma 10 64 9.4 4.03 × 10–7 1.71 × 10–6 8 4.79 7.48 × 10–3
Glycan structures – biosynthesis 1 11 122 5.7 1.22 × 10–6 6.90 × 10–6 9 2.79 3.65 × 10–2
Colorectal cancer 12 84 7.1 2.03 × 10–6 8.74 × 10–6 10 3.38 3.01 × 10–2
For differentially expressed genes, P values of less than 0.05 and fold changes of less than –1.5 or more than 1.5 were used. Uncorr., uncorrected;  
Corr. γ, corrected γ.
Table 2
Significant KEGG pathways — mouse Qkfgt/gt adult dorsal cortex expression versus wild-type expression
	 Pathway-Express	calculation	 DAVID	functional	annotation
	 P	value
KEGG	pathway	name	 Rank	 No.	genes	 %	Pathway	genes	 Uncorr.	 Corr.	γ	 Rank	 Fold	 P	value
	 	 in	pathway	 in	input	 	 	 	 enrichment
Neuroactive ligand-receptor 1 256 4.3 5.80 × 10–12 4.93 × 10–11 1 3.01 4.45 × 10–3
 interaction
Axon guidance 4 128 4.7 6.12 × 10–7 7.58 × 10–7 2 3.66 2.12 × 10–2
Calcium signaling pathway 3 185 3.8 1.71 × 10–7 3.10 × 10–7 3 3.10 2.21 × 10–2
MAPK signaling pathway 2 258 3.5 9.84 × 10–9 1.08 × 10–8 4 2.44 3.90 × 10–2
For differentially expressed genes, P values of less than 0.05 and fold changes of less than –1.5 or more than 1.5 were used.
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Significant KEGG pathways — mouse Qkfgt/gt E12.5 dorsal telencephalon expression versus wild-type expression
	 Pathway-Express	calculation	 DAVID	functional	annotation
	 P	value
KEGG	pathway	name	 Rank	 No.	genes	 %	Pathway	genes	 Uncorr.	 Corr.	γ	 Rank	 Fold	 P	value
	 	 in	pathway	 in	input	 	 	 	 enrichment
MAPK signaling pathway 2 258 4.3 4.37 × 10–9 8.70 × 10–9 1 1.77 3.15 × 10–4
Insulin signaling pathway 3 137 6.6 2.68 × 10–9 1.60 × 10–8 2 1.94 2.18 × 10–3
Type II diabetes mellitus 6 46 8.7 2.85 × 10–5 1.62 × 10–5 3 2.59 7.64 × 10–3
Wnt signaling pathway 7 145 4.1 2.15 × 10–5 1.77 × 10–5 7 1.65 2.28 × 10–2
Acute myeloid leukemia 45 58 3.4 2.09 × 10–2 3.14 × 10–2 8 2.09 3.27 × 10–2
Cell cycle 22 109 3.7 8.51 × 10–4 2.56 × 10–3 10 1.69 3.91 × 10–2
GnRH signaling pathway 25 95 3.2 5.96 × 10–3 4.78 × 10–3 11 1.77 3.97 × 10–2
For differentially expressed genes, P values of less than 0.05 and fold changes of less than –1.5 or more than 1.5 were used.
Table 4
Significant KEGG pathways of genes with ChIP-on-CHIP binding sites
	 Pathway-Express	calculation	 DAVID	functional	annotation
	 P	value
KEGG	pathway	name	 Rank	 No.	genes	 %	Pathway	genes	 Uncorr.	 Corr.	γ	 Rank	 Fold	 P	value
	 	 in	pathway	 in	input	 	 	 	 enrichment
MAPK signaling pathway 3 265 3.0 4.89 × 10–7 3.60 × 10–7 2 2.46 3.81 × 10–2
Thyroid cancer 5 29 6.9 2.76 × 10–3 8.16 × 10–4 1 11.78 4.21 × 10–3
ChIP-on-CHIP MAT score P value of less than 0.05.
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Significant KEGG pathways of significant differentially expressed genes with ChIP-on-CHIP binding sites
	 Pathway-Express	calculation	 DAVID	functional	annotation
	 P	value
KEGG	pathway	name	 Rank	 No.	genes	 %	Pathway	genes	 Uncorr.	 Corr.	γ	 Rank	 Fold	 P	value
	 	 in	pathway	 in	input	 	 	 	 enrichment
MAPK signaling pathway 4 272 4.0 4.82 × 10–2 1.72 × 10–2 2 2.48 2.41 × 10–2
Thyroid cancer 8 29 6.9 1.46 × 10–1 2.45 × 10–2 1 10.58 5.73 × 10–3
For differentially expressed genes, P values of less than 0.05 were used; ChIP-on-CHIP MAT score P values of less than 0.05.
Figure 6
Biochemical characterization of MEK, ERK, and AKT phos-
phorylation levels. (A) Increased MAPK signaling activity of 
the patient (P1) containing the MYST4 mutation compared 
with 3 control samples (C1–C3). The patient cell line tran-
siently transfected with an MYST4 wild-type construct (R) 
demonstrated a normalization of the phosphorylation levels. 
Cells were analyzed for the phosphorylation level of MEK/
pMEK1/2 (MAP2K/pMAP2K1/2), ERK/pERK1/2, and AKT/
pAKT. Total amounts of MEK, ERK, and AKT and actin in 
cell lysates are shown, and the specificity of the antibody is 
specified below each panel. (B) After normalization to actin, 
densitometric analysis confirmed significantly increased 
ratios of all 3 measured parameters (*P < 0.05, t test) and 
normalization to wild-type ratios after rescue of MYST4 
expression levels.
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The MAPK signaling pathway. Overview of genes with ChIP-CHIP binding sites and differential expression. Three out of the four major branches 
of the MAPK signaling pathway are shown: ERK1/2 (MAP2K1/2), c-Jun, and p38 (modified from KEGG pathway map 04010; http://www.genome.
jp/kegg/). Mutations affecting the ERK1/2 (MAP2K1/2) branch are identified in approximately 70% of patients with Noonan syndrome (genes 
marked with orange stars). Note that genes with significant ChIP-on-CHIP bindings sites (Supplemental Table 23) are marked in yellow; addi-
tional significantly differentially expressed genes in the human cell lines are marked with red boxes.
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m1),  PPP3CB  (Hs00184176_m1),  and MAP2K3  (Hs00177127_m1) 
and, 2 unaltered control genes, NTRK1 (Hs01021011_m1) and DUSP2 
(Hs00358879_m1).
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genetic  mechanisms  in  neurological  diseases: 
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